Clinical Trial Update: Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) [Phase 3]

View source ↗

Summary

Merck completed the Phase 3 HPV vaccination registration study (Gardasil, V501-023) with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2010-09-14